Research Centers for Improving Management of Symptoms Across Cancer Treatments (IMPACT) (UM1)

The summary for the Research Centers for Improving Management of Symptoms Across Cancer Treatments (IMPACT) (UM1) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Research Centers for Improving Management of Symptoms Across Cancer Treatments (IMPACT) (UM1): This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative established to accelerate cancer research. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): the Implementation of Integrated and Evidenced-based Symptom Management Throughout the Cancer Trajectory. The purpose of this specific FOA is to promote research on the implementation and evaluation of integrated symptom monitoring and management systems for use in cancer care delivery through a Research Consortium. This research will provide new insights and valuable evidence that can be used to guide efforts on a nation-wide basis to improve symptom control for cancer patients during treatment and survivorship.

Federal Grant Title:	Research Centers for Improving Management of Symptoms Across Cancer Treatments (IMPACT) (UM1)
Federal Agency Name:	National Institutes of Health (HHS-NIH11)
Grant Categories:	Education Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-CA-17-042
Type of Funding:	Cooperative Agreement
CFDA Numbers:	93.395
CFDA Descriptions:	Information not provided
Current Application Deadline:	January 17th, 2018
Original Application Deadline:	January 17th, 2018
Posted Date:	October 18th, 2017
Creation Date:	October 18th, 2017
Archive Date:	February 22nd, 2018
Total Program Funding:	$5,400,000
Maximum Federal Grant Award:	$1,120,000
Minimum Federal Grant Award:
Expected Number of Awards:	3
Cost Sharing or Matching:	No
Last Updated:	October 18th, 2017

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Public and State controlled institutions of higher education - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-17-042.html
Grant Announcement Contact: NIH OER Webmaster
[email protected]

If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
Similar Government Grants: • The Experimental Therapeutics Clinical Trials Network (ETCTN) Pharmacokinetic Resource Lab...; • The Experimental Therapeutics Clinical Trials Network (ETCTN) Lead Academic Organizations ...; • Toward Translation of Nanotechnology Cancer Interventions (TTNCI; R01 Clinical Trial Not A...; • Assay development and screening for discovery of chemical probes, drugs or immunomodulator...; • Specialized Programs of Research Excellence (SPOREs) in Cancer Health Disparities and Mino...; • Breast and Prostate Cancer Data Quality and Patterns of Care Study; • Consortium Therapeutic Studies of Primary Central Nervous System Malignancies in Adults; • National Cooperative Drug Discovery Groups for Cancer
More Grants from the National Institutes of Health: • Translational Centers Using Microphysiological Systems for Infectious Diseases (U54 Clinic...; • Immune Tolerance Network (UM1 Clinical Trial Required); • Coordinating Center for National Resource Network for the Study of Human Auditory and Vest...; • National Resource Network for the Study of Human Auditory and Vestibular Disorders (U24 Cl...; • Pilot and Feasibility Studies in Preparation for Substance Use and HIV Prevention Interven...